Loading…
Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand
The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the te...
Saved in:
| Published in: | PloS one 2021-02, Vol.16 (2), p.e0246864 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3 |
| container_end_page | |
| container_issue | 2 |
| container_start_page | e0246864 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Putcharoen, Opass Wacharapluesadee, Supaporn Chia, Wan Ni Paitoonpong, Leilani Tan, Chee Wah Suwanpimolkul, Gompol Jantarabenjakul, Watsamon Ruchisrisarod, Chanida Wanthong, Phanni Sophonphan, Jiratchaya Chariyavilaskul, Pajaree Wang, Lin-Fa Hemachudha, Thiravat |
| description | The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the test sensitivity. Thus, specimens with low IgM/ IgG antibody levels showed strong neutralization activity in sVNT.
This study aimed to measure the %inhibition of NAbs measured by sVNT in PCR-confirmed COVID-19 patients. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection and its kinetics were determined.
Ninety-seven patients with PCR-confirmed SARS-CoV-2 infection were included in this study. Majority of the patients were 21-40 years old (67%) and 63% had mild symptoms. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection was 99% (95% confidence interval (CI) 94.4-100%) and the specificity was 100% (95% CI 98.3-100%). The negative predictive value of sVNT from the samples collected before and after 7 days of symptom onset was 99.5% (95% CI 97.4-100%) and 100% (95% CI 93.8-100%), respectively. The level of inhibition at days 8-14 were significantly higher than days 0-7 (p |
| doi_str_mv | 10.1371/journal.pone.0246864 |
| format | article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2489009750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651631757</galeid><doaj_id>oai_doaj_org_article_44fb7a80fb0643fba8f68231d73524c4</doaj_id><sourcerecordid>A651631757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QLguhFx3w1aW-EYVx1YGFgZ51LQ5omnQydZGxScf31pk53mcpeSC9STp_znp435yTJSwhmEDP4Yef6zop2dnBWzQAitKDkUXIOS4wyigB-fPJ-ljzzfgdAjgtKnyZnGOeMUZifJ98vRdfeprUKSgbjbOp0alUfOtGa38Y2qbDBVK42yqeiEcb6kK7n1-ts4TYZSo1NF6vN8lMGy_QgglE2-CF4sxWmFbZ-njzRovXqxXheJN8-X94svmZXqy_Lxfwqk7REISNAIFLrUha6UiVCZYE0gQhWFQBICoYhBVLWiNU6J5VWShJIGcupqlSuhMAXyeuj7qF1no_WeI5IUQJQshxEYnkkaid2_NCZvehuuROG_w24ruGiC0a2ihOiKyYKoCtACdaVKDQtEIY1wzkikkStj2O1vtqrWsauo18T0ekXa7a8cT85KwpAEIsC70aBzv3olQ98b7xUbbRMuf7434gCSIqIvvkHfbi7kWpEbMBY7WJdOYjyOc0hxZDlQ9nZA1R8arU3Ms6RNjE-SXg_SYhMUL9CI3rv-XJ9_f_sajNl356wWyXasPWu7YcJ9FOQHEHZOe87pe9NhoAPa3DnBh_WgI9rENNenV7QfdLd3OM_srEA3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489009750</pqid></control><display><type>article</type><title>Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central Free</source><source>Coronavirus Research Database</source><creator>Putcharoen, Opass ; Wacharapluesadee, Supaporn ; Chia, Wan Ni ; Paitoonpong, Leilani ; Tan, Chee Wah ; Suwanpimolkul, Gompol ; Jantarabenjakul, Watsamon ; Ruchisrisarod, Chanida ; Wanthong, Phanni ; Sophonphan, Jiratchaya ; Chariyavilaskul, Pajaree ; Wang, Lin-Fa ; Hemachudha, Thiravat</creator><contributor>Jin, Dong-Yan</contributor><creatorcontrib>Putcharoen, Opass ; Wacharapluesadee, Supaporn ; Chia, Wan Ni ; Paitoonpong, Leilani ; Tan, Chee Wah ; Suwanpimolkul, Gompol ; Jantarabenjakul, Watsamon ; Ruchisrisarod, Chanida ; Wanthong, Phanni ; Sophonphan, Jiratchaya ; Chariyavilaskul, Pajaree ; Wang, Lin-Fa ; Hemachudha, Thiravat ; Jin, Dong-Yan</creatorcontrib><description>The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the test sensitivity. Thus, specimens with low IgM/ IgG antibody levels showed strong neutralization activity in sVNT.
This study aimed to measure the %inhibition of NAbs measured by sVNT in PCR-confirmed COVID-19 patients. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection and its kinetics were determined.
Ninety-seven patients with PCR-confirmed SARS-CoV-2 infection were included in this study. Majority of the patients were 21-40 years old (67%) and 63% had mild symptoms. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection was 99% (95% confidence interval (CI) 94.4-100%) and the specificity was 100% (95% CI 98.3-100%). The negative predictive value of sVNT from the samples collected before and after 7 days of symptom onset was 99.5% (95% CI 97.4-100%) and 100% (95% CI 93.8-100%), respectively. The level of inhibition at days 8-14 were significantly higher than days 0-7 (p<0.001). The median %inhibition values by severity of COVID-19 symptoms were 79.9% (interquartile range (IQR) 49.7-91.8%); 89.0% (IQR 71.2-92.4%); and 86.6% (IQR 69.5-92.8%), for mild, moderate and severe/critical symptoms respectively. The median level of sVNT %inhibition of severe was significantly higher than the mild group (p = 0.05).
The sVNT is a practical and robust serological test for SARS-CoV-2 infection and does not require specialized biosafety containment. It can be used clinically to aid diagnosis in both early and late infection especially in cases when the real-time RT-PCR results in weakly negative or weakly positive, and to determine the protective immune response from SARS-CoV-2 infection in patients.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0246864</identifier><identifier>PMID: 33577615</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Antibodies ; Antibodies, Neutralizing - analysis ; Antibodies, Neutralizing - isolation & purification ; Antibodies, Viral - isolation & purification ; Asymptomatic infection ; Biology and life sciences ; Contact tracing ; Coronaviruses ; Cough ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - immunology ; COVID-19 Nucleic Acid Testing ; COVID-19 Serological Testing - methods ; Editing ; Electronic mail ; Female ; Fever ; HIV ; Hospitals ; Human immunodeficiency virus ; Humans ; Humoral immunity ; Immune response ; Immune system ; Infections ; Infectious diseases ; Male ; Measurement ; Medicine ; Medicine and health sciences ; Metropolitan areas ; Middle Aged ; Myalgia ; Neutralization Tests - methods ; Nose ; Olfaction ; Pandemics ; Patients ; Pediatrics ; Pharmacogenomics ; Pharmacokinetics ; Pharmacology ; Pneumonia ; Polymerase chain reaction ; Public health ; Research and Analysis Methods ; SARS-CoV-2 - physiology ; Sensitivity and Specificity ; Serologic Tests ; Serology ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Smell ; Spike Glycoprotein, Coronavirus - chemistry ; Thailand ; Training ; Vaccines ; Viral antibodies ; Viral diseases ; Viral infections ; Viruses ; Young Adult ; Zoonoses</subject><ispartof>PloS one, 2021-02, Vol.16 (2), p.e0246864</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Putcharoen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Putcharoen et al 2021 Putcharoen et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3</citedby><cites>FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3</cites><orcidid>0000-0001-8444-8512 ; 0000-0003-4251-3499</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2489009750?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2489009750?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33577615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Jin, Dong-Yan</contributor><creatorcontrib>Putcharoen, Opass</creatorcontrib><creatorcontrib>Wacharapluesadee, Supaporn</creatorcontrib><creatorcontrib>Chia, Wan Ni</creatorcontrib><creatorcontrib>Paitoonpong, Leilani</creatorcontrib><creatorcontrib>Tan, Chee Wah</creatorcontrib><creatorcontrib>Suwanpimolkul, Gompol</creatorcontrib><creatorcontrib>Jantarabenjakul, Watsamon</creatorcontrib><creatorcontrib>Ruchisrisarod, Chanida</creatorcontrib><creatorcontrib>Wanthong, Phanni</creatorcontrib><creatorcontrib>Sophonphan, Jiratchaya</creatorcontrib><creatorcontrib>Chariyavilaskul, Pajaree</creatorcontrib><creatorcontrib>Wang, Lin-Fa</creatorcontrib><creatorcontrib>Hemachudha, Thiravat</creatorcontrib><title>Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the test sensitivity. Thus, specimens with low IgM/ IgG antibody levels showed strong neutralization activity in sVNT.
This study aimed to measure the %inhibition of NAbs measured by sVNT in PCR-confirmed COVID-19 patients. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection and its kinetics were determined.
Ninety-seven patients with PCR-confirmed SARS-CoV-2 infection were included in this study. Majority of the patients were 21-40 years old (67%) and 63% had mild symptoms. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection was 99% (95% confidence interval (CI) 94.4-100%) and the specificity was 100% (95% CI 98.3-100%). The negative predictive value of sVNT from the samples collected before and after 7 days of symptom onset was 99.5% (95% CI 97.4-100%) and 100% (95% CI 93.8-100%), respectively. The level of inhibition at days 8-14 were significantly higher than days 0-7 (p<0.001). The median %inhibition values by severity of COVID-19 symptoms were 79.9% (interquartile range (IQR) 49.7-91.8%); 89.0% (IQR 71.2-92.4%); and 86.6% (IQR 69.5-92.8%), for mild, moderate and severe/critical symptoms respectively. The median level of sVNT %inhibition of severe was significantly higher than the mild group (p = 0.05).
The sVNT is a practical and robust serological test for SARS-CoV-2 infection and does not require specialized biosafety containment. It can be used clinically to aid diagnosis in both early and late infection especially in cases when the real-time RT-PCR results in weakly negative or weakly positive, and to determine the protective immune response from SARS-CoV-2 infection in patients.</description><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - analysis</subject><subject>Antibodies, Neutralizing - isolation & purification</subject><subject>Antibodies, Viral - isolation & purification</subject><subject>Asymptomatic infection</subject><subject>Biology and life sciences</subject><subject>Contact tracing</subject><subject>Coronaviruses</subject><subject>Cough</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 Nucleic Acid Testing</subject><subject>COVID-19 Serological Testing - methods</subject><subject>Editing</subject><subject>Electronic mail</subject><subject>Female</subject><subject>Fever</subject><subject>HIV</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Humoral immunity</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Measurement</subject><subject>Medicine</subject><subject>Medicine and health sciences</subject><subject>Metropolitan areas</subject><subject>Middle Aged</subject><subject>Myalgia</subject><subject>Neutralization Tests - methods</subject><subject>Nose</subject><subject>Olfaction</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacogenomics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Pneumonia</subject><subject>Polymerase chain reaction</subject><subject>Public health</subject><subject>Research and Analysis Methods</subject><subject>SARS-CoV-2 - physiology</subject><subject>Sensitivity and Specificity</subject><subject>Serologic Tests</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Smell</subject><subject>Spike Glycoprotein, Coronavirus - chemistry</subject><subject>Thailand</subject><subject>Training</subject><subject>Vaccines</subject><subject>Viral antibodies</subject><subject>Viral diseases</subject><subject>Viral infections</subject><subject>Viruses</subject><subject>Young Adult</subject><subject>Zoonoses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QLguhFx3w1aW-EYVx1YGFgZ51LQ5omnQydZGxScf31pk53mcpeSC9STp_znp435yTJSwhmEDP4Yef6zop2dnBWzQAitKDkUXIOS4wyigB-fPJ-ljzzfgdAjgtKnyZnGOeMUZifJ98vRdfeprUKSgbjbOp0alUfOtGa38Y2qbDBVK42yqeiEcb6kK7n1-ts4TYZSo1NF6vN8lMGy_QgglE2-CF4sxWmFbZ-njzRovXqxXheJN8-X94svmZXqy_Lxfwqk7REISNAIFLrUha6UiVCZYE0gQhWFQBICoYhBVLWiNU6J5VWShJIGcupqlSuhMAXyeuj7qF1no_WeI5IUQJQshxEYnkkaid2_NCZvehuuROG_w24ruGiC0a2ihOiKyYKoCtACdaVKDQtEIY1wzkikkStj2O1vtqrWsauo18T0ekXa7a8cT85KwpAEIsC70aBzv3olQ98b7xUbbRMuf7434gCSIqIvvkHfbi7kWpEbMBY7WJdOYjyOc0hxZDlQ9nZA1R8arU3Ms6RNjE-SXg_SYhMUL9CI3rv-XJ9_f_sajNl356wWyXasPWu7YcJ9FOQHEHZOe87pe9NhoAPa3DnBh_WgI9rENNenV7QfdLd3OM_srEA3A</recordid><startdate>20210212</startdate><enddate>20210212</enddate><creator>Putcharoen, Opass</creator><creator>Wacharapluesadee, Supaporn</creator><creator>Chia, Wan Ni</creator><creator>Paitoonpong, Leilani</creator><creator>Tan, Chee Wah</creator><creator>Suwanpimolkul, Gompol</creator><creator>Jantarabenjakul, Watsamon</creator><creator>Ruchisrisarod, Chanida</creator><creator>Wanthong, Phanni</creator><creator>Sophonphan, Jiratchaya</creator><creator>Chariyavilaskul, Pajaree</creator><creator>Wang, Lin-Fa</creator><creator>Hemachudha, Thiravat</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8444-8512</orcidid><orcidid>https://orcid.org/0000-0003-4251-3499</orcidid></search><sort><creationdate>20210212</creationdate><title>Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand</title><author>Putcharoen, Opass ; Wacharapluesadee, Supaporn ; Chia, Wan Ni ; Paitoonpong, Leilani ; Tan, Chee Wah ; Suwanpimolkul, Gompol ; Jantarabenjakul, Watsamon ; Ruchisrisarod, Chanida ; Wanthong, Phanni ; Sophonphan, Jiratchaya ; Chariyavilaskul, Pajaree ; Wang, Lin-Fa ; Hemachudha, Thiravat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - analysis</topic><topic>Antibodies, Neutralizing - isolation & purification</topic><topic>Antibodies, Viral - isolation & purification</topic><topic>Asymptomatic infection</topic><topic>Biology and life sciences</topic><topic>Contact tracing</topic><topic>Coronaviruses</topic><topic>Cough</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 Nucleic Acid Testing</topic><topic>COVID-19 Serological Testing - methods</topic><topic>Editing</topic><topic>Electronic mail</topic><topic>Female</topic><topic>Fever</topic><topic>HIV</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Humoral immunity</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Measurement</topic><topic>Medicine</topic><topic>Medicine and health sciences</topic><topic>Metropolitan areas</topic><topic>Middle Aged</topic><topic>Myalgia</topic><topic>Neutralization Tests - methods</topic><topic>Nose</topic><topic>Olfaction</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacogenomics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Pneumonia</topic><topic>Polymerase chain reaction</topic><topic>Public health</topic><topic>Research and Analysis Methods</topic><topic>SARS-CoV-2 - physiology</topic><topic>Sensitivity and Specificity</topic><topic>Serologic Tests</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Smell</topic><topic>Spike Glycoprotein, Coronavirus - chemistry</topic><topic>Thailand</topic><topic>Training</topic><topic>Vaccines</topic><topic>Viral antibodies</topic><topic>Viral diseases</topic><topic>Viral infections</topic><topic>Viruses</topic><topic>Young Adult</topic><topic>Zoonoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Putcharoen, Opass</creatorcontrib><creatorcontrib>Wacharapluesadee, Supaporn</creatorcontrib><creatorcontrib>Chia, Wan Ni</creatorcontrib><creatorcontrib>Paitoonpong, Leilani</creatorcontrib><creatorcontrib>Tan, Chee Wah</creatorcontrib><creatorcontrib>Suwanpimolkul, Gompol</creatorcontrib><creatorcontrib>Jantarabenjakul, Watsamon</creatorcontrib><creatorcontrib>Ruchisrisarod, Chanida</creatorcontrib><creatorcontrib>Wanthong, Phanni</creatorcontrib><creatorcontrib>Sophonphan, Jiratchaya</creatorcontrib><creatorcontrib>Chariyavilaskul, Pajaree</creatorcontrib><creatorcontrib>Wang, Lin-Fa</creatorcontrib><creatorcontrib>Hemachudha, Thiravat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Putcharoen, Opass</au><au>Wacharapluesadee, Supaporn</au><au>Chia, Wan Ni</au><au>Paitoonpong, Leilani</au><au>Tan, Chee Wah</au><au>Suwanpimolkul, Gompol</au><au>Jantarabenjakul, Watsamon</au><au>Ruchisrisarod, Chanida</au><au>Wanthong, Phanni</au><au>Sophonphan, Jiratchaya</au><au>Chariyavilaskul, Pajaree</au><au>Wang, Lin-Fa</au><au>Hemachudha, Thiravat</au><au>Jin, Dong-Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-02-12</date><risdate>2021</risdate><volume>16</volume><issue>2</issue><spage>e0246864</spage><pages>e0246864-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the test sensitivity. Thus, specimens with low IgM/ IgG antibody levels showed strong neutralization activity in sVNT.
This study aimed to measure the %inhibition of NAbs measured by sVNT in PCR-confirmed COVID-19 patients. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection and its kinetics were determined.
Ninety-seven patients with PCR-confirmed SARS-CoV-2 infection were included in this study. Majority of the patients were 21-40 years old (67%) and 63% had mild symptoms. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection was 99% (95% confidence interval (CI) 94.4-100%) and the specificity was 100% (95% CI 98.3-100%). The negative predictive value of sVNT from the samples collected before and after 7 days of symptom onset was 99.5% (95% CI 97.4-100%) and 100% (95% CI 93.8-100%), respectively. The level of inhibition at days 8-14 were significantly higher than days 0-7 (p<0.001). The median %inhibition values by severity of COVID-19 symptoms were 79.9% (interquartile range (IQR) 49.7-91.8%); 89.0% (IQR 71.2-92.4%); and 86.6% (IQR 69.5-92.8%), for mild, moderate and severe/critical symptoms respectively. The median level of sVNT %inhibition of severe was significantly higher than the mild group (p = 0.05).
The sVNT is a practical and robust serological test for SARS-CoV-2 infection and does not require specialized biosafety containment. It can be used clinically to aid diagnosis in both early and late infection especially in cases when the real-time RT-PCR results in weakly negative or weakly positive, and to determine the protective immune response from SARS-CoV-2 infection in patients.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33577615</pmid><doi>10.1371/journal.pone.0246864</doi><tpages>e0246864</tpages><orcidid>https://orcid.org/0000-0001-8444-8512</orcidid><orcidid>https://orcid.org/0000-0003-4251-3499</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-02, Vol.16 (2), p.e0246864 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2489009750 |
| source | Access via ProQuest (Open Access); PubMed Central Free; Coronavirus Research Database |
| subjects | Adult Antibodies Antibodies, Neutralizing - analysis Antibodies, Neutralizing - isolation & purification Antibodies, Viral - isolation & purification Asymptomatic infection Biology and life sciences Contact tracing Coronaviruses Cough COVID-19 COVID-19 - diagnosis COVID-19 - immunology COVID-19 Nucleic Acid Testing COVID-19 Serological Testing - methods Editing Electronic mail Female Fever HIV Hospitals Human immunodeficiency virus Humans Humoral immunity Immune response Immune system Infections Infectious diseases Male Measurement Medicine Medicine and health sciences Metropolitan areas Middle Aged Myalgia Neutralization Tests - methods Nose Olfaction Pandemics Patients Pediatrics Pharmacogenomics Pharmacokinetics Pharmacology Pneumonia Polymerase chain reaction Public health Research and Analysis Methods SARS-CoV-2 - physiology Sensitivity and Specificity Serologic Tests Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Smell Spike Glycoprotein, Coronavirus - chemistry Thailand Training Vaccines Viral antibodies Viral diseases Viral infections Viruses Young Adult Zoonoses |
| title | Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A58%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20detection%20of%20neutralizing%20antibodies%20against%20SARS-CoV-2%20in%20COVID-19%20patients%20in%20Thailand&rft.jtitle=PloS%20one&rft.au=Putcharoen,%20Opass&rft.date=2021-02-12&rft.volume=16&rft.issue=2&rft.spage=e0246864&rft.pages=e0246864-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0246864&rft_dat=%3Cgale_plos_%3EA651631757%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-40a24df9c8fbe922982f4121bb002ca73160ccd27df54bfeec4167756ebe5eaa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2489009750&rft_id=info:pmid/33577615&rft_galeid=A651631757&rfr_iscdi=true |